On September 13, 2022, Shanghai Luoqi Bio-pharmaceutical Technology Co., Ltd. announced the appointment of Ms. Huang Jing as the company's chief business officer, mainly responsible for the brand strategy of Luoqi Bio-market, including business development, financing, government affairs docking, etc.

       Ms. Huang Jing has nearly 20 years of pharmaceutical and medical market experience, and has rich experience in product positioning, business development, market strategy formulation and implementation.

       Before joining Loqi, he worked in relevant start-ups, multinational scientific instrument companies and front-line CROs, and worked successively in Yujing Technology (Shanghai) Co., Ltd., the strategic director of the global clinical business department of Waterworld Technology (Shanghai) Co., Ltd., the director of the market department of Greater China, and Shanghai Pharmaceuticals New Drug Development Co., Ltd.

        Ms. Huang Jing holds a bachelor's degree in chemistry from Nanjing University, a master's degree in engineering from Hefei University of Technology, and an EMBA from the University of Montpellier in France (under study). She has one provincial science and technology progress award and one invention patent.

2022年9月13日

Ms. Huang Jing said: I am very happy to join the Loqi team. Loqi Biology is a company dedicated to the research of innovative drugs for nano-antibody, and also the only company in China that has the ability to develop the whole process of nano-antibody drugs. It has a good reputation and great popularity in the biomedical industry. I hope that after joining Loqi, we can make progress together with Loqi and play a greater role.

Dr. Wan Yakun, founder and general manager of Luoqi Biology, said: On behalf of all colleagues of Luoqi Biology, I would like to extend a warm welcome to Ms. Huang Jing. At the same time, it is also expected that Ms. Huang Jing's many years of experience of the industry elite will help Loki Biology to develop a higher and further strategic plan and accelerate the mission of "providing patients with newer and safer innovative drugs".